Literature DB >> 17701586

Predictive value and diagnostic accuracy of F-18-fluoro-deoxy-glucose positron emission tomography treated grade 1 and 2 follicular lymphoma.

Shrinivas Bishu1, Joanna M Quigley, Shreenath R Bishu, Sarah M Olsasky, Richard A Stem, Valerie K Shostrom, Karen P Holdeman, Subash Paknikar, James O Armitage, Jordan H Hankins.   

Abstract

F-18-fluoro-deoxy-glucose positron emission tomography (PET) is a powerful tool for the imaging of aggressive B-cell lymphomas. In contrast, there is relatively little data on PET in follicular lymphoma grade 1 (FL-1) and grade 2 (FL-2). In this manuscript, we present our findings utilizing PET in treated FL-1 and FL-2. A retrospective review of patients who underwent PET examinations at our institution produced 95 PET examinations among 31 patients with FL-1 and FL-2. PET was obtained at initial staging, mid-induction and post-treatment. Results were compared with clinical follow-up. PET had high sensitivity (95%) and specificity (88%) for lesion detection in treated FL-1 and FL-2. Abnormal foci in FL-1 and FL-2 had similar intensities. Post-induction PET positive patients had shorter mean progression free survivals compared with PET negative patients (p-value < or =0.001), post-salvage PET positive trended toward shorter mean response duration compared with negative patients (p-value: 0.09). Our results indicate that PET is accurate in the diagnostic assessment of treated FL-1 and FL-2 and, post-treatment PET positive patients are likely to relapse prior to PET negative patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17701586     DOI: 10.1080/10428190701422059

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  16 in total

Review 1.  Consolidation radioimmunotherapy of follicular lymphoma: a step towards cure?

Authors:  Jean-François Chatal; Françoise Kraeber-Bodéré; Jacques Barbet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-07       Impact factor: 9.236

2.  Early FDG-PET response-adapted risk stratification and further therapeutic decision-making in lymphoma: will this replace the established prognostic indices and be the standard-of-care in clinical management?

Authors:  Sandip Basu
Journal:  Eur J Nucl Med Mol Imaging       Date:  2009-10-28       Impact factor: 9.236

3.  C-MOPP: the forgotten regimen plus Rituximab for untreated and relapsed follicular lymphoma.

Authors:  Mark J Fesler; Medhat Osman; James Glauber; Paul J Petruska
Journal:  Am J Blood Res       Date:  2011-09-22

4.  [Importance of PET/CT in lymphoma diagnostics].

Authors:  A Afshar-Oromieh; C Kratochwil; U Haberkorn; F L Giesel
Journal:  Radiologe       Date:  2012-04       Impact factor: 0.635

5.  Diagnostic and prognostic impact of 18F-FDG PET/CT in follicular lymphoma.

Authors:  Ludovic Le Dortz; Sophie De Guibert; Sahar Bayat; Anne Devillers; Roch Houot; Yan Rolland; Marc Cuggia; Florence Le Jeune; Haïfa Bahri; Marie-Luce Barge; Thierry Lamy; Etienne Garin
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-08-18       Impact factor: 9.236

6.  PET/CT assessment in follicular lymphoma using standardized criteria: central review in the PRIMA study.

Authors:  Christelle Tychyj-Pinel; Fabien Ricard; Michael Fulham; Marion Fournier; Michel Meignan; Thierry Lamy; Pierre Vera; Gilles Salles; Judith Trotman
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-01-17       Impact factor: 9.236

7.  [18F] Positron emission tomography response after rituximab-containing induction therapy in follicular lymphoma is an independent predictor of survival after adjustment for FLIPI in academic and community-based practice.

Authors:  Ida Wong-Sefidan; Michelle Byrtek; Xiaolei Zhou; Jonathan W Friedberg; Christopher R Flowers; Andrew D Zelenetz; Keith L Dawson; Erin Reid
Journal:  Leuk Lymphoma       Date:  2016-08-12

8.  Current status of PET/CT in the diagnosis and follow up of lymphomas.

Authors:  Carlos Alberto Buchpiguel
Journal:  Rev Bras Hematol Hemoter       Date:  2011

Review 9.  Current role of FDG PET/CT in lymphoma.

Authors:  Lale Kostakoglu; Bruce D Cheson
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-02-12       Impact factor: 9.236

10.  A phase 2 trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701.

Authors:  Barbara W Grant; Sin-Ho Jung; Jeffrey L Johnson; Lale Kostakoglu; Eric Hsi; John C Byrd; Jeffrey Jones; John P Leonard; S Eric Martin; Bruce D Cheson
Journal:  Cancer       Date:  2013-08-06       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.